Will the FDA approve CagriSema?

Before Jan 1, 2027

1.34x

Before Jul 1, 2027

1.20x

$6,850 vol4 markets

Biotech

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

Yes

1.02x

No

13.4x

$3,409 vol1 market

Medicine

When will the FDA reclassify BPC-157 to Category 1?

Before 2027

2.66x

Before November

7.85x

$100,877 vol2 markets

Medicine

When will Beam Therapeutics submit a BLA for Risto-cel?

before December

1.90x

before 2027

1.60x

$23,973 vol5 markets

Medicine

When will Compass Pathways submit a NDA for COMP360 psilocybin?

before November

1.73x

before 2027

1.28x

$20,817 vol5 markets

Biotech

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes

1.31x

No

2.98x

$1,143 vol1 market

Medicine

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

Before Jan 1, 2027

2.46x

Before Mar 1, 2027

1.31x

$19,586 vol5 markets

Eli Lilly

Will the FDA approve retatrutide?

Before Jul 1, 2027

2.09x

Before Jan 1, 2028

1.14x

$39,611 vol5 markets

Biotech

FDA decision: Venglustat by Sanofi (this year)

Yes

1.16x

No

4.51x

$816 vol1 market

Medicine

Will the FDA approve a cure for Type 1 diabetes before 2033?

Yes

2.46x

No

1.57x

$9,831 vol1 market

Biotech

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes

1.36x

No

2.89x

$8,576 vol1 market

Eli Lilly

Will the FDA approve VERVE-102?

Before 2030

1.70x

Before 2031

1.42x

$1,733 vol6 markets

Medicine

When will the FDA approve Intellia Therapeutics’ lonvo-z?

Before 2028

1.08x

Before July 2027

1.07x

$6,310 vol3 markets

Biotech

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

Yes

1.01x

No

15.6x

$4,044 vol1 market

Biotech

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes

1.06x

No

7.85x

$831 vol1 market

Biotech

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes

1.05x

No

8.56x

$2,814 vol1 market

Tech & Science

Tech & Science

Medicine

Medicine

Will the FDA approve CagriSema?

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

When will the FDA reclassify BPC-157 to Category 1?

When will Beam Therapeutics submit a BLA for Risto-cel?

When will Compass Pathways submit a NDA for COMP360 psilocybin?

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

Will the FDA approve retatrutide?

FDA decision: Venglustat by Sanofi (this year)

Will the FDA approve a cure for Type 1 diabetes before 2033?

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Will the FDA approve VERVE-102?

When will the FDA approve Intellia Therapeutics’ lonvo-z?

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Will the FDA approve CagriSema?

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

When will the FDA reclassify BPC-157 to Category 1?

When will Beam Therapeutics submit a BLA for Risto-cel?

When will Compass Pathways submit a NDA for COMP360 psilocybin?

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

Will the FDA approve retatrutide?

FDA decision: Venglustat by Sanofi (this year)

Will the FDA approve a cure for Type 1 diabetes before 2033?

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Will the FDA approve VERVE-102?

When will the FDA approve Intellia Therapeutics’ lonvo-z?

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)